First randomized Phase III trial confirming the efficacy of MET inhibition in patients with advanced NSCLC and acquired MET amplification after ...

BioNTech's gotistobart receives FDA orphan drug designation, showing promise in improving survival for patients with squamous ...

Labcorp added to its suite of tests designed to detect cancer recurrence much earlier than traditional imaging.

Labcorp , a global leader of innovative and comprehensive laboratory services, today announced the continued expansion of its molecular residual disease (MRD)i portfolio designed to help clinicians ...

The first patient has been dosed in the TROPION-Lung17 phase 3 trial evaluating DATROWAY® (datopotamab deruxtecan) compared to docetaxel in patients with TROP2 NMR positive locally advanced or ...

RVMD stays a Strong Buy as RAS inhibitor trials advance; phase 3 RASolute-302 is a key 2026 catalyst. Read the latest ...

Experts discuss the critical unmet needs in HER2-mutant non-small cell lung cancer, highlighting disparities in testing and ...

Experts explore HER2 mutations and the critical role of comprehensive molecular profiling in optimizing treatment for ...

Biomarker testing has become “increasingly critical” in the care of non-small cell lung cancer.A new investigation into testing rates proved “reassuring” to Kenneth L. Kehl, MD, MPH, assistant ...

In Brazil, the early detection of genetic alterations in lung cancer through liquid biopsies could be a valuable tool for ...

Medicaid expansion under the ACA improved long-term survival for younger adults with operable lung cancer, despite no earlier ...

Experts discuss the underutilization of biomarker testing in metastatic lung cancer, emphasizing the need for improved ...